Cytokinetics | CYTK

Stock Price
38.63
Daily Change
1.77%
Yearly
-9.93%
Q2 Forecast
37.51
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Eisai 9,500.00 450.00 4.97% 82.48%
Arca Biopharma 2.11 0.01 0.48% -10.59%
Acadia Pharmaceuticals 24.61 0.71 2.97% 37.49%
Acorda Therapeutics 0.50 -0.05 -9.35% 67.33%
Amgen 218.07 3.80 1.77% -12.23%
Bayer 52.61 0.71 1.37% -20.43%
Brainstorm Cell Therapeutics 3.04 0.10 3.40% 0.66%
Biogen 300.20 -2.21 -0.73% 49.64%
Bristol-Myers Squibb 65.66 0.98 1.52% -12.65%
Capricor Therapeutics 4.55 0 0% 25.00%
Cytokinetics 38.63 0.67 1.77% -9.93%
Exelixis 19.19 -0.20 -1.03% 0.79%
Geron 3.60 0.22 6.51% 160.87%
Halozyme Therapeutics 33.57 1.08 3.32% -26.41%
Ionis Pharmaceuticals 41.75 -1.19 -2.77% 15.49%
Intra Cellular Therapies 61.32 1.79 3.01% 5.09%
Ligand Pharmaceuticals 75.31 4.11 5.77% -11.32%
Eli Lilly 442.22 5.84 1.34% 46.60%
Merck & Co 112.52 1.59 1.43% 25.15%
Novartis 89.37 1.31 1.49% 4.12%
Pfizer 38.36 0.34 0.89% -27.89%
Regeneron Pharmaceuticals 739.95 8.78 1.20% 17.39%
Roche Holding 292.80 3.05 1.05% -8.70%
Sanofi 94.98 0.77 0.82% -5.08%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%
US2000 1831 62.97 3.56% -2.77%

Cytokinetics

Cytokinetics traded at $38.63 this Friday June 2nd, increasing $0.67 or 1.77 percent since the previous trading session. Looking back, over the last four weeks, Cytokinetics gained 1.80 percent. Over the last 12 months, its price fell by 9.93 percent. Looking ahead, we forecast Cytokinetics to be priced at 37.51 by the end of this quarter and at 34.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.